-
A Beacon of Hope: UTRX-MYCN-M1 Receives FDA Orphan and Rare Pediatric Designations
A Significant Milestone for Neuroblastoma Research In a promising development for pediatric oncology, UTR Therapeutics Inc. has officially announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation and Rare Pediatric Disease Designation to its therapeutic candidate, UTRX-MYCN-M1. This candidate is currently being developed for the treatment of neuroblastoma, a rare…
-
Atossa Therapeutics Reinforces Z-Endoxifen’s Value Following Priority Review Voucher Program Reauthorization
NASDAQ: $ATOS Atossa Therapeutics, Inc. has underscored the continued strategic significance of its lead drug candidate, Z-Endoxifen, for the treatment of Duchenne Muscular Dystrophy (DMD). This reinforcement comes directly on the heels of recent legislative action by the U.S. Congress to reauthorize the Priority Review Voucher (PRV) program. Z-Endoxifen and the Importance of the PRV…